Malignant pleural mesothelioma - An update

被引:11
作者
Stewart, DJ
Edwards, JG
Smythe, WR
Waller, DA
O'Byrne, KJ
机构
[1] Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Dept Oncol, Leicester LE1 5WW, Leics, England
[2] Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Dept Thorac Surg, Leicester LE1 5WW, Leics, England
[3] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
关键词
neoplasm; mesothelioma; epidemiology; diagnosis; chemotherapy; surgery; radiotherapy; novel therapies;
D O I
10.1179/oeh.2004.10.1.26
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Exposure to asbestos is the most frequent,but not exclusive, cause of malignant mesothelioma.. Clinical features include dyspnea, cough, nonspecific chest pain, weight loss and night sweats. Diagnosis may be complicated by histologic difficulties. Thoracoscopic techniques are proving beneficial, but no one method of imaging has proven superior, and disease staging is inconsistent. Conventional treatments such as chemotherapy, surgery, and radiotherapy have had variable impacts, although chemotherapy is useful in palliation and can improve both survival and quality of life. There is hope for new antimetabolite agents. The,role of radical surgery is yet to be evaluated in a large trial. New radiotherapeutic techniques to improve local control are promising. Multimodality treatments appear to be the most successful for management of potentially resectable disease. It is likely that biological markers will improve accuracy in staging and prognosis. With new treatments based on better understanding of the biology of the disease, there is cautious optimism for the future for patients with malignant pleural mesothelioma.
引用
收藏
页码:26 / 39
页数:14
相关论文
共 186 条
[1]   Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies [J].
Abutaily, AS ;
Addis, BJ ;
Roche, WR .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (09) :662-668
[2]   Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma [J].
Adams, RF ;
Gray, W ;
Davies, RJO ;
Gleeson, FV .
CHEST, 2001, 120 (06) :1798-1802
[3]   Intensity-modulated radiation therapy: A novel approach to the management of malignant pleural mesothelioma [J].
Ahamad, A ;
Stevens, CW ;
Smythe, WR ;
Vaporciyan, AA ;
Komaki, R ;
Kelly, JF ;
Liao, ZX ;
Starkschall, G ;
Forster, KM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (03) :768-775
[4]  
ASTOUL P, 1994, CANCER, V73, P308, DOI 10.1002/1097-0142(19940115)73:2<308::AID-CNCR2820730213>3.0.CO
[5]  
2-4
[6]   Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies [J].
Baas, P ;
Murrer, L ;
Zoetmulder, FAN ;
Stewart, FA ;
Ris, HB ;
vanZandwijk, N ;
Peterse, JL ;
Rutgers, EJT .
BRITISH JOURNAL OF CANCER, 1997, 76 (06) :819-826
[7]   Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine [J].
Baas, P .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :62-69
[8]   Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma [J].
Bakhshandeh, A ;
Bruns, I ;
Traynor, A ;
Robins, HI ;
Eberhardt, K ;
Demedts, A ;
Kaukel, E ;
Koschel, G ;
Gatzemeier, U ;
Kohlmann, T ;
Dalhoff, K ;
Ehlers, EM ;
Gruber, Y ;
Zumschlinge, R ;
Hegewisch-Becker, S ;
Peters, SO ;
Wiedemann, GJ .
LUNG CANCER, 2003, 39 (03) :339-345
[9]  
Baldini EH, 1997, ANN THORAC SURG, V63, P334
[10]  
BASS P, 2002, P 6 M INT MES INT GR